We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

228 hedge funds and large institutions have $2.31B invested in Celldex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 67 increasing their positions, 58 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 14

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

23% more funds holding

Funds holding: 185 → 228 (+43)

16% more capital invested

Capital invested by funds: $2B → $2.31B (+$314M)

16% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 58

1.19% less ownership

Funds ownership: 110.21% → 109.01% (-1.2%)

38% less call options, than puts

Call options by funds: $3.79M | Put options by funds: $6.1M

Holders
228
Holders Change
+43
Holders Change %
+23.24%
% of All Funds
2.81%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.11%
New
60
Increased
67
Reduced
58
Closed
14
Calls
$3.79M
Puts
$6.1M
Net Calls
-$2.31M
Net Calls Change
-$3.85M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$40.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.1M
3
IC
Ikarian Capital
Texas
+$12.6M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$11.1M
5
EP
Eversept Partners
New York
+$9.63M

Top Sellers

1
BG
Bellevue Group
Switzerland
-$65.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.6M
3
PCH
Polar Capital Holdings
United Kingdom
-$27.4M
4
DTC
Deep Track Capital
Connecticut
-$16.8M
5
EAM
Eventide Asset Management
Massachusetts
-$16.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
JF
151
Jump Financial
Illinois
$280K -$3.72M -136,344 -94%
Russell Investments Group
152
Russell Investments Group
United Kingdom
$269K +$36.8K +1,349 +19%
EFM
153
E Fund Management
China
$259K +$223K +8,178 New
Walleye Capital
154
Walleye Capital
New York
$258K +$222K +8,147 New
Public Employees Retirement Association of Colorado
155
Public Employees Retirement Association of Colorado
Colorado
$247K – – –
AQR Capital Management
156
AQR Capital Management
Connecticut
$247K +$212K +7,777 New
JG
157
Jain Global
New York
$246K +$212K +7,763 New
Teacher Retirement System of Texas
158
Teacher Retirement System of Texas
Texas
$246K -$30.6K -1,121 -13%
EC
159
EntryPoint Capital
New York
$236K +$203K +7,430 New
AC
160
AXQ Capital
New Jersey
$230K +$197K +7,237 New
Cetera Investment Advisers
161
Cetera Investment Advisers
Illinois
$228K -$73.6K -2,699 -27%
DT
162
Diversified Trust
Tennessee
$223K +$191K +7,021 New
TCA
163
Transcend Capital Advisors
New Jersey
$210K -$71.6K -2,626 -28%
PIA
164
Panoramic Investment Advisors
Colorado
$206K +$177K +6,500 New
Canada Life
165
Canada Life
Manitoba, Canada
$202K – – –
Ensign Peak Advisors
166
Ensign Peak Advisors
Utah
$199K – – –
TRCT
167
Tower Research Capital (TRC)
New York
$177K +$112K +4,109 +279%
AIP
168
Ameritas Investment Partners
Nebraska
$174K – – –
ACM
169
Aquatic Capital Management
Illinois
$163K +$140K +5,130 New
ASN
170
Advisory Services Network
Georgia
$147K +$126K +4,625 New
CIAM
171
Caitong International Asset Management
Hong Kong
$83.3K +$71K +2,603 +11,832%
QT
172
Quantbot Technologies
New York
$78.4K +$63.4K +2,326 +1,593%
KBC Group
173
KBC Group
Belgium
$76K – – –
PWPS
174
Pinnacle Wealth Planning Services
Ohio
$71.1K – – –
SCM
175
Sterling Capital Management
North Carolina
$68.8K -$44.7K -1,639 -43%
5 6
7
8 9

CLDX Hedge Fund Activity: Q1 2026 in Review

228 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2026, worth a combined $2.31B — up 16% from $2B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new CLDX positions and 14 closed out — a net gain of 46 holders — while 67 added to existing stakes and 58 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $40.1M. The largest seller was Bellevue Group, cutting an estimated $65.9M.

  • 228 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2026, up from 185 in Q4 2025.
  • Funds reported $2.31B of Celldex Therapeutics stock for Q1 2026, up 16% quarter-over-quarter.
  • 60 funds opened new Celldex Therapeutics positions in Q1 2026 and 14 closed out, a net change of +46 holders.
  • The largest Celldex Therapeutics buyer in Q1 2026 was Point72 Asset Management, an estimated $40.1M added.
  • The largest Celldex Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $65.9M sold.

Based on aggregated 13F filings for Q1 2026.